Advertisement

Rheumatology International

, Volume 32, Issue 5, pp 1437–1441 | Cite as

Possible anti-metastatic effect of Iloprost in a patient with systemic sclerosis with lung cancer: a case study

  • Yavuz PehlivanEmail author
  • Ibrahim Halil Turkbeyler
  • Ozan Balakan
  • Alper Sevinc
  • Mustafa Yilmaz
  • Kemal Bakir
  • Ahmet Mesut Onat
Short Communication

Abstract

Systemic Sclerosis (SSc) is a chronic disease of unknown etiology which affects the vascular system and connective tissue. A wide series of studies showed an increased prevalence of cancer in patients with SSc than the normal population. Prostacyclin (PGI2) is an endogenously produced element that is basically synthesized by arachiodonic acid through prostacyclin synthesis in vascular system endothelial cells. Iloprost is a stable analogue of PGI2 which is used in the treatment of pulmonary arterial hypertension (PAH). In a limited number of animal models, the anti-metastatic activity of PGI2 is observed. Herein, we report iloprost treatment of a 60-year-old-woman with SSc, who lately developed PAH as a complication of her disease and lung adenocarcinoma as a co-incidence simultaneously. These two mortal complications were both treated successfully with inhaled iloprost until her death due to gastrointestinal complications of SSc.

Keywords

Lung adenocarcinoma Prostacyclin analogue Inhaled iloprost Anti-metastatic activity Pulmonary arterial hypertension Systemic Sclerosis 

References

  1. 1.
    Gilliland BC (2005) Systemic sclerosis and related disorders. In: Kasper DL, Braunwald E, Fauci AS, Hauser SL, Longo DL, Jameson JL (eds) Harrison principles of internal medicine, 6th edn. New York, Mc Graw-Hill, pp 1979–1990Google Scholar
  2. 2.
    Abu-Shakra M, Guillemin F, Lee P (1993) Cancer in systemic sclerosis. Arthritis Rheum 36:460–464PubMedCrossRefGoogle Scholar
  3. 3.
    Yang Y, Fujita J, Tokuda M, Bandoh S, Ishida T (2001) Lung cancer associated with several connective tissue diseases: with a review of literature. Rheumatol Int 21:106–111PubMedCrossRefGoogle Scholar
  4. 4.
    Goldsmith DR, Wagstaff A (2004) Inhaled iloprost in primary pulmonary hypertension. Drugs 64:763–773PubMedCrossRefGoogle Scholar
  5. 5.
    Scott JP, Higenbottam T, Wallwork J (1990) The acute effect of synthetic prostacyclin analogue iloprost in primary pulmonary hypertension. Br J Clin Pract 44:231–234PubMedGoogle Scholar
  6. 6.
    Black CM (1995) The aetiopathogenesis of systemic sclerosis: thick skin-thin hypotheses. The parkes weber lecture. J R Coll Physicians Lond 29:119–130PubMedGoogle Scholar
  7. 7.
    Siau K, Laversuch CJ, Creamer P, O’Rourke KP (2010) Malignancy in scleroderma patients from south west England: a population-based cohort study. Rheumatol Int. 8. [Epub ahead of print]Google Scholar
  8. 8.
    Chatterjee S, Dombi GW, Severson RK, Mayes MD (2005) Risk of malignancy in scleroderma. A population-based cohort study. Arthritis Rheum 52:2415–2424PubMedCrossRefGoogle Scholar
  9. 9.
    Moncada S, Gryglewski R, Bunting S, Vane JR (1976) An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature 263:663–665PubMedCrossRefGoogle Scholar
  10. 10.
    Belch JJ (1987) Effect of iloprost (ZK 36374) on white cell behaviour. In: Gryglewski RJ, Stock G (eds) Prostacyclin and its stable analogue iloprost. Springer-Verlang, Berlin- Heidelberg, pp 97–102CrossRefGoogle Scholar
  11. 11.
    Stürzebecher CS (1987) Effects of iloprost on platelet activation in vitro. In: Gryglewski RJ, Stock G (eds) Prostacyclin and its stable analogue iloprost. Springer, Berlin-Heidelberg, pp 39–45CrossRefGoogle Scholar
  12. 12.
    Wigley FM, Wise RA, Seibold JR, McCloskey DA, Kujala G, Medsger TA Jr, Steen VD, Varga J, Jimenes S, Mayes M (1994) Inrtavenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sklerosis. A multicenter, placebo-controlled, double-blind study. Ann Intern Med 120:199–206PubMedGoogle Scholar
  13. 13.
    Gasic GJ (1984) Role of plasma, platelets and endothelial cells in tumour metastasis. Cancer Metastasis Rev 3:99–116PubMedCrossRefGoogle Scholar
  14. 14.
    Honn KV, Cicone B, Skoff A (1981) Prostacyclin: a potent antimetastatic agent. Science 212:1270–1272PubMedCrossRefGoogle Scholar
  15. 15.
    Sava G, Perisin L, Zorzet S, Piccini P, Giraldi T (1989) Antimetastatic action of the prostacyclin anologue Iloprost in the Mouse. Clinical and Experimental Meastasis 7:671–678CrossRefGoogle Scholar
  16. 16.
    Schirner M, Schneider MR (1991) Cicaprost inhibits metastases of animal tumours. Prostaglandins 42:451–461PubMedCrossRefGoogle Scholar
  17. 17.
    Menter DG, Onoda JM, Taylor JD, Honn KV (1984) Effect of prostacyclin on tumour cell-induced platelet aggregation. Cancer Res 44:450–456PubMedGoogle Scholar
  18. 18.
    Tang DG, Grossi IM, Tang KQ, Diglio CA, Honn KV (1995) Inhibition of TPA and 12(S)-HETE-stimulated tumour cell adhesion by prostacyclin and its stable analogs: rationale for their antimetastatic effects. Int J Cancer 60:418–425PubMedCrossRefGoogle Scholar
  19. 19.
    Schneider MR, Schillinger E, Schirner M, Skuballa W, Stürzebecher S, Witt W (1991) Effects of prostacyclin analogues in in vivo tumour models. Adv Prostaglandin Thromboxane Leukot Res 21:901–908Google Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • Yavuz Pehlivan
    • 1
    Email author
  • Ibrahim Halil Turkbeyler
    • 2
  • Ozan Balakan
    • 3
  • Alper Sevinc
    • 3
  • Mustafa Yilmaz
    • 4
  • Kemal Bakir
    • 5
  • Ahmet Mesut Onat
    • 1
  1. 1.School of Medicine, Departments of Rheumatologyn, Sahinbey Medical CenterGaziantep UniversityGaziantepTurkey
  2. 2.School of Medicine, Departments of Internal Medicine, Sahinbey Medical CenterGaziantep UniversityGaziantepTurkey
  3. 3.School of Medicine, Departments of Medical Oncology, Gaziantep Oncology HospitalGaziantep UniversityGaziantepTurkey
  4. 4.School of Medicine, Departments of Nukleer Medicine, Gaziantep Oncology HospitalGaziantep UniversityGaziantepTurkey
  5. 5.School of Medicine, Departments of Pathology, Sahinbey Medical CenterGaziantep UniversityGaziantepTurkey

Personalised recommendations